Cyclodextrin-Derived Drug Delivery Systems in Respiratory Diseases

Respiratory diseases like chronic obstructive pulmonary disease (COPD), chronic bronchitis, asthma, lung cancer, tuberculosis (TB), pneumonia, and, currently, respiratory infection due to novel Coronavirus (2019-nCoV) have been the major cause of concern these days and pose a serious challenge before the medical practitioners. Various types of dosage forms, surgeries, and radiotherapies are available as the major treatment options; however, these approaches are of limited use in the successful management of the above disorders and some seem very expensive. Conventional dosage form-based therapies have many disadvantages, including poor bioavailability, safety issues, poor site specificity, and drug resistance. In recent years, with the recent advancement in research and development, different novel drug delivery approaches have been aimed for comprehensive management of various types of respiratory diseases. Cyclodextrins (CDs) based formulations played a significant role in improving the treatment of respiratory diseases. It is utilized to improve the drug’s physicochemical properties, however, some of its derivatives offer direct therapeutic efficacy. In this chapter, the derivates of CD, provided with their sources and physicochemical properties, are discussed with their applications in treating major lung diseases like COPD, chronic bronchitis, asthma, lung cancer, pulmonary fibrosis, pneumonia, etc. We have also aimed to showcase, based on the ongoing clinical trials, the recent translational potential of CD-based drug delivery systems used in the respiratory disease therapy.